熱門資訊> 正文
Allogene Therapeutics和Arbor Biotechnologies宣佈全球基因編輯許可協議，以支持下一代異體CAR T平臺在自身免疫性疾病中的發展
2024-03-12 20:57
Allogene's AlloCAR T Autoimmune Disease Platform Leverages Arbor's CRISPR Gene-Editing TechnologyFirst Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune Disease Expected to Initiate in Early 2025SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, and Arbor Biotechnologies, Inc. ("Arbor"), a biotechnology company discovering and developing the next generation of genetic medicines, today announced a non-exclusive, global gene editing licensing agreement for use of Arbor's proprietary CRISPR gene-editing technology in
